Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy

Gerty Schreibelt, Kalijn F. Bol, Erik H.J.G. Aarntzen, Winald R. Gerritsen, Cornelis J.A. Punt, Carl G. Figdor, I. Jolanda M. De Vries

Research output: Contribution to journalArticlepeer-review


Dendritic cell-based anticancer immunotherapy is feasible, safe and results in the induction of tumor-specific immune responses, at least in a fraction of vaccinated patients. The concomitant activation of cytotoxic andhelper T cells, by loading DCs with peptides or electroporating them with the corresponding mRNAs, may further enhance vaccineinduced antitumor responses.

Original languageEnglish (US)
Article numbere24440
Issue number6
StatePublished - Jun 2013


  • Cancer immunotherapy
  • Dendritic cell vaccination
  • Helper T cells
  • Metastatic melanoma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology


Dive into the research topics of 'Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy'. Together they form a unique fingerprint.

Cite this